Navigation Links
Patient Safety Technologies Reports Second Quarter 2011 Results

IRVINE, Calif., Aug. 16, 2011 /PRNewswire/ -- Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced financial results for its second quarter of 2011 ended June 30, 2011.

Financial HighlightsDuring the second quarter of 2011, the number of institutions using the Company's SurgiCount Safety-Sponge® System surpassed 70 and the Company lost no customers.  This compares to approximately 52 institutions using the solution at the end of the second quarter of 2010.  Although not necessarily proportional to reported revenue, the number of hospitals using the Company's products is a good indicator of our underlying business.

Total revenue for the quarter ended June 30, 2011 was $2.6 million, which included $0.5 million of revenue from the delivery to the Company's exclusive distributor as part of a $10.0 million inventory stocking order.  Excluding the effect of this inventory stocking order, revenue for the quarter ended June 30, 2011 was $2.1 million.  This compares with total revenue for the quarter ended June 30, 2010 of $3.8 million, which included $2.3 million of revenue from the delivery under the same $10 million inventory stocking order.  Excluding the effect of this inventory stocking order, revenue for the second quarter of 2010 would have been $1.4 million.  Accordingly, excluding the effects of this inventory stocking order, revenue for the three months ended June 30, 2011 of $2.1 million represents approximately 50% growth over the $1.4 million generated for the three months ended June 30, 2010.
This growth in revenue excluding the effects of the stocking order is primarily the result of the significant growth in the number of hospitals using the Safety-Sponge® System at the end of the second quarter of 2011 as compared to the second quarter of 2010.  Additionally, during the second quarter 2011, the Company successfully completed the delivery of the last of the $10.0 million stocking order.  

As a result of a comprehensive restructuring program begun in the third quarter of 2010 focused on a number of initiatives including reducing cash operating expenses, our operating expenses in the second quarter of 2011 were reduced significantly as compared to the second quarter of 2010.  Reported GAAP operating expenses were $1.7 million and $3.0 million for the second quarters of 2011 and 2010, respectively, a decrease of $1.3 million or 44%.  Excluding non-cash expenses for stock compensation and depreciation, our operating expenses in the second quarter 2011 were 50% of what the comparable expenses were in second quarter 2010.  

As a direct result of the continued growth of the Company's customer base and reported revenues excluding stocking orders, combined with the success of the restructuring program, the Company generated an Adjusted Operating Loss (defined as reported operating income adjusted to exclude certain non-cash expenses) of $23 thousand during the second quarter of 2011.  This compares with an Adjusted Operating Loss of $332 thousand during the second quarter of 2010.  

The Company ended the second quarter of 2011 with $5.7 million of cash and cash equivalents and no debt.  Additionally, the Company anticipates that the $224 thousand of restricted cash reported at quarter end will be released during the third quarter of 2011.  Including this restricted cash, total cash and cash equivalents at the end of the second quarter were $5.9 million.

Expanded customer baseCurrent users of the SurgiCount Safety-Sponge® System include over 70 hospitals, including six of the 17 hospitals named to the U.S. News and World Report 2011-12 Best Hospitals Honor Roll.  Additionally, as previously disclosed, during the second quarter of 2011 use of the Safety-Sponge® System surpassed 50 million sponges successfully used in over 2.5 million procedures.

"During the second quarter we continued to add to the list of hospitals who are taking a proactive step to improve their patient outcomes and reduce their preventable costs through the use of the Safety-Sponge® System.  With additional hospitals already under contract in the third quarter, we are well positioned to continue to grow our user base, revenues and profitability," said Brian E. Stewart, President and Chief Executive Officer of Patient Safety Technologies.

The Company's second quarter 2011 financial statements are included in its Quarterly Report on Form 10-Q filed by the company on August 15th, 2011 and available at the SEC's website at  

Reconciliation of GAAP to Non-GAAP Results (Unaudited)Non-GAAP Measures($ in 000's)

Three Months EndedSix Months EndedJune 30,June 30,2011201020112010Reported Operating Loss($411.6)($1,028.0)($1,242.5)($2,431.4)Plus:Stock based compensation



804.5Depreciation and amortization



440.2Adjusted Operating Loss($23.2)($331.5)($573.8)($1,186.7)To supplement the Company's presentation of operating income measured in accordance with GAAP, we also use a non-GAAP measure of operating income, herein defined as Adjusted Operating Income (in the event this amount is negative herein defined as Adjusted Operating Loss). Reconciliation to GAAP operating income from Adjusted Operating Income or Loss is included immediately above in this press release.  The Adjusted Operating Losses shown above are not adjusted to include the effect of certain costs estimated to be non-recurring in nature of $134 thousand and $268 thousand during Q2 2011 and Q2 2010, respectively.  These estimated non-recurring costs included a number of expenses estimated to be one-time in nature such as certain severance expenses and other non-recurring expenses that management estimates are not reflective of ongoing operating results.

Non-GAAP measures are provided to enhance investors' overall understanding of the Company's current financial performance, prospects for the future and as a means to evaluate period-to-period comparisons. The Company believes that the use of non-GAAP operating income provides meaningful supplemental information regarding financial performance by excluding certain expenses and benefits that may not be indicative of recurring core business operating results. The Company believes this non-GAAP measure, which excludes the non-cash expenses of depreciation, amortization and stock based compensation, when viewed with GAAP results and the accompanying reconciliation, enhances the comparability of results against prior periods and allows for greater transparency of financial results.  The Company believes this non-GAAP measure facilitates management's internal comparison of the Company's financial performance to that of prior periods as well as trend analysis for budgeting and planning purposes. The presentation of this non-GAAP measure is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

About Patient Safety Technologies, Inc. and SurgiCount MedicalPatient Safety Technologies, Inc., through its wholly-owned operating subsidiary SurgiCount Medical, Inc., provides the Safety-Sponge® System, a solution proven to improve patient safety and reduce healthcare costs by preventing one of the most common errors in surgery, retained foreign objects.  For more information, contact SurgiCount Medical, Inc. at (949) 387-2277 or visit

Forward Looking Statements

Statements in this press release regarding our business that are not historical facts are "forward-looking statements" (within the meaning of Section 21E of the Securities Exchange Act of 1934) that involve risks and uncertainties. Forward-looking statements reflect our management's current views with respect to future events and financial performance; however, you should not put undue reliance on these statements.  When used, the words "anticipates," "believes," "expects," "intends," "future," and other similar expressions, without limitation, identify forward-looking statements.  Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. These factors and uncertainties include but are not limited to: the early stage of adoption of our Safety-Sponge® System and the need to expand adoption of our Safety-Sponge® System; the impact on our future revenue and cash flows from the ordering patterns of our exclusive distributor Cardinal Health; our need for additional financing to support our business; our reliance on third-party manufacturers, some of whom are sole-source suppliers, and on our exclusive distributor; and any inability to successfully protect our intellectual property portfolio.  In light of the risks and uncertainties, there can be no assurance that any forward-looking statement will in fact prove to be correct.

Forward-looking statements can be affected by many other factors, including, those described in the "Business", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Factors Affecting Future Results" sections of our Annual Report on Form 10-K for 2010, our Quarterly Reports on Form 10-Q and in our other public filings. These documents are available online through the SEC's website, Forward-looking statements are based on information presently available to senior management, and we have not assumed any duty to update any forward-looking statements.

PATIENT SAFETY TECHNOLOGIES, INC.Condensed Consolidated Balance SheetsJune 30,2011December 31,2010(Unaudited)AssetsCurrent assets:Cash and cash equivalents$


1,896,034Restricted cash223,630223,630Accounts receivable675,594772,381Inventories, net1,193,3341,110,832Prepaid expenses43,813104,628Total current assets7,849,4924,107,505Property and equipment, net932,641979,833Goodwill1,832,0271,832,027Patents, net2,626,6122,789,083Other assets52,21339,038Total assets$


9,747,486Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$


2,605,669Warrant derivative liability767,060991,682Deferred revenue375,9501,477,720Accrued liabilities419,354942,472Total current liabilities3,236,8956,017,543Stockholders' equity Total stockholders' equity10,056,0903,729,943Total liabilities and stockholders' equity$


9,747,486PATIENT SAFETY TECHNOLOGIES, INC.Condensed Consolidated Statements of Operations(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010Revenues$




6,130,337Cost of revenue1,296,1301,790,3602,337,2312,879,248Gross profit1,272,6401,975,1572,202,1953,251,089Operating expenses:Research and development24,29897,97253,760131,302Sales and marketing674,416828,4451,333,4521,822,562General and administrative985,5842,076,7762,057,4803,728,638Total operating expenses1,684,2983,003,1933,444,6925,682,502Operating loss(411,658)(1,028,036)(1,242,497)(2,431,413)Other income (expense)Interest income (expense)213(796)(3,979)(13,042)Gain on change in fair value of warrant der. liab.14,360951,210224,6222,669,949Other income (expense)227,617(5,075)227,61752,782Total other income242,190945,339448,2602,709,689(Loss) income before income taxes(169,468)(82,697)(794,237)278,276Income tax (benefit) provision-32,573(3,773)65,146Net (loss) income(169,468)(50,124)(798,010)343,422Preferred dividends(124,103)(25,932)(248,062)(45,095)Net (loss) income  applicable to common shareholders$




298,327(Loss) income per common shareBasic$








0.01Weighted average common shares outstanding:Basic33,517,84523,456,06328,857,95223,456,063Diluted33,517,84523,456,06328,857,95224,895,607

SOURCE Patient Safety Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):